| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8453609 | Lung Cancer | 2018 | 36 Pages |
Abstract
Roniciclib co-administered with chemotherapy in patients with ED-SCLC demonstrated tolerability, acceptable pharmacokinetics, and promising efficacy. An observed safety signal in a related phase II study resulted in discontinuation of the present study and termination of further roniciclib development.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Byoung Chul Cho, Grace K. Dy, Ramaswamy Govindan, Dong-Wan Kim, Nathan A. Pennell, Gerard Zalcman, Benjamin Besse, Joo-Hang Kim, Goekben Koca, Prabhu Rajagopalan, Simon Langer, Matthias Ocker, Hendrik Nogai, Fabrice Barlesi,